(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone has been researched along with arachidonyl-2-chloroethylamide in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, P; Goutopoulos, A; Khanolkar, AD; Lin, S; Makriyannis, A; Papahadjis, D; Qin, C | 1 |
| Benetti, V; Castelli, MP; Cavallini, T; Ferrarini, PL; Lazzarotti, S; Manera, C; Martinelli, A; Pibiri, F; Saccomanni, G; Tuccinardi, T; Vannacci, A | 1 |
| Allarà, M; Benetti, V; Cascio, MG; Di Marzo, V; Ferrarini, PL; Ghelardini, C; Manera, C; Martinelli, A; Saccomanni, G; Tuccinardi, T; Vivoli, E | 1 |
| Buzard, DJ; Han, S; Jones, RM; Thatte, J | 1 |
| Arena, C; Bertini, S; Carpi, S; Cervetto, C; Chicca, A; Chicca, S; D'Andrea, F; Di Cesare Mannelli, L; Digiacomo, M; Gado, F; Gertsch, J; Ghelardini, C; Lucarini, E; Macchia, M; Manera, C; Marcoli, M; Nieri, P; Poli, G; Polini, B; Reynoso-Moreno, I; Tuccinardi, T; Vallini, E | 1 |
1 review(s) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and arachidonyl-2-chloroethylamide
| Article | Year |
|---|---|
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Topics: Animals; Drug Design; Humans; Ligands; Models, Molecular; Molecular Conformation; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Substrate Specificity | 2013 |
4 other study(ies) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and arachidonyl-2-chloroethylamide
| Article | Year |
|---|---|
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Brain; Cannabinoids; Endocannabinoids; Guanosine 5'-O-(3-Thiotriphosphate); In Vitro Techniques; Mice; Polyunsaturated Alkamides; Radioligand Assay; Rats; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug; Serine Proteinase Inhibitors; Spleen; Structure-Activity Relationship; Tosyl Compounds | 1998 |
Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
Topics: Amides; Animals; Basophils; Brain; Drug Design; Guanosine 5'-O-(3-Thiotriphosphate); Humans; In Vitro Techniques; Ligands; Male; Mice; Mice, Inbred DBA; Models, Molecular; Naphthyridines; Phosphoric Diester Hydrolases; Pyrophosphatases; Quinolines; Radioligand Assay; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Thermodynamics | 2006 |
New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.
Topics: Animals; Cell Line; Humans; Mice; Naphthyridines; Pain Measurement; Quinolines; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2007 |
The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Female; Ligands; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Multiple Sclerosis; Protein Binding; Pyridones; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2020 |